Fig. 5

Effect of CLM against insulin resistance (a-c), exhibiting that the total HOMA-IR in the CLM group was substantially reduced at 6 weeks (*p = 0.046) and 12 weeks (**p = 0.018), while the placebo group was slightly increased (a). While maintaining normal HOMA-IR range in the participants whose insulin resistance was normal (initial HOMA < 1.66) through 6 weeks (*p = 0.5344) and 12 weeks (**p = 0.438) (b), a dramatic reduction was observed in the CLM group (initial HOMA-IR > 1.66) at 6 weeks (*p = 0.026) and 12 weeks (**p = 0.007) (c)